Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of antiplatelet therapy with cangrelor in patients with coronary stents undergoing surgery
2018-004446-42Phase 2Active
- Sponsor
- Ospedale Santa Croce e Carle
- Start
- Jan 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cangrelor in coronary arteriosclerosis, sponsored by Ospedale Santa Croce e Carle. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Jan 2021; status: active.
02
Drugs
cangrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2018-004446-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004446-42.